SCHEMBL7682901

SCHEMBL7682901

CCOC(=O)Cc1cc(CC)c(C(=O)c2ccc(Cl)cc2)n1CC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 2/20 0.44
ABCB11 O95342 1/20 0.44
ALDH1A1 P00352 4/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
CYP1A2 P05177 2/20 0.42
TSHR P16473 2/20 0.42
LMNA P02545 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
RAB9A P51151 1/20 0.40
MAPK1 P28482 2/20 0.40
MAPT P10636 3/20 0.39
CXCR3 P49682 1/20 0.38
CFTR P13569 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7678562 0.87 PTGS2 (0.57) PTGS2ABCB11ALDH1A1SMN1; SMN2CYP1A2
SCHEMBL7675690 0.78 PTGS2 (0.73) PTGS2ABCB11ALDH1A1SMN1; SMN2CYP1A2
SCHEMBL7683471 0.77 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2TSHRTDP1RAB9A
SCHEMBL11713094 0.76 PTGS2 (0.56) PTGS2ABCB11ALDH1A1SMN1; SMN2CYP1A2
SCHEMBL11614944 0.76 HPGD (0.40) PTGS2ABCB11ALDH1A1SMN1; SMN2LMNA
SCHEMBL11401313 0.76 PTGS2 (0.55) PTGS2ABCB11ALDH1A1SMN1; SMN2CYP1A2
SCHEMBL10879085 0.75 PTGS2 (0.55) PTGS2ABCB11ALDH1A1SMN1; SMN2CYP1A2
SCHEMBL11194335 0.75 PTGS2 (0.55) PTGS2ABCB11ALDH1A1SMN1; SMN2CYP1A2
SCHEMBL7681896 0.75 NOD2 (0.38) ALDH1A1SMN1; SMN2RAB9AMAPTCYP2C9
SCHEMBL11714065 0.74 PTGS2 (0.59) PTGS2ABCB11ALDH1A1SMN1; SMN2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6455703-B2 ADMINISTERING EFFECTIVE AMOUNT OF 1,3,6-TRIHYDRO-6-AZA-3-OXAPENTALEN-2-ONE DERIVATIVE TO THE PATIENT FOR INDUCING OR PROMOTING APOPTOSIS AND FOR ARRESTING UNCONTROLLED NEOPLASTIC CELL PROLIFERATION CELL PATHWAYS, INC. 2002-09-24 US disclosed
US-20010051651-A1 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia OSI PHARMACEUTICALS, INC. 2001-12-13 US disclosed
US-6160003-A 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia CELL PATHWAYS, INC. (US) 2000-12-12 US disclosed
US-5939417-A 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia CELL PATHWAYS INC (US) 1999-08-17 US disclosed
US-4255335-A Preparation of 5-aroyl-1-loweralkylpyrrole-2-acetic acid derivatives MCNEILAB, INC. (US) 1981-03-10 US disclosed
US-3952012-A MULTISTAGE MCNEIL LABORATORIES, INCORPORATED (US) 1976-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010051651-A1 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia MALT1, VHL, CDKN1A PTGS2 887/4885ABCB11 2317/4885ALDH1A1 208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.